Nasdaq · Biotech stocks database
LFVN — Lifevantage Corporation ☆
LFVN (Lifevantage Corporation) stock: $5.22, $65.7M market cap, $14.9M cash, $50.8M EV, $68.0M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants. We sell our products in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, Iceland, and Portugal.
Source: 10-K FY2026 via SEC EDGAR
Balance sheet
Cash $14.9M Debt $0.0M Net cash $14.9M Enterprise value $50.8M Basic shares 12.5M shares Fully diluted shares 13.0M shares Fully diluted market cap $68.0M Cash per share $1.19 Quarterly burn +$4.8M generated
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2026-08-26.
Price history Loading LFVN daily closes…
Loading price history…
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.